News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Russia launched a coordinated missile and drone assault on Ukraine, killing two, wounding 19, and prompting Kyiv to demand expedited air‑defence munitions.
  • China ordered major refineries to maintain or raise processing rates as Persian Gulf tensions raise crude shipment disruption risks.
  • U.S. Rep. Ro Khanna says armed Israeli settlers detained him and his delegation during a West Bank visit before police intervened.
  • Emergency teams moved from containment to active attack as a wildfire in Almería killed 12 and forced precautionary evacuations.
  • Morgan Stanley finds U.S. companies increasingly reporting measurable profit and productivity gains from AI, supporting corporate earnings outlooks.
  • Analysts recommend buy‑the‑dip trades in AI and recovery names like Palantir and CoreWeave, while highlighting defensive income picks such as Pfizer and Atlanticus.

Latest Articles

Citi Start Boosts Figma Shares as Analyst Cites AI Monetization Pathways

Citi Start Boosts Figma Shares as Analyst Cites AI Monetization Pathways

Figma Inc. shares climbed 5% on Wednesday after Citi initiated coverage with a buy rating and a $36 price target. Analyst Tyler Radke highlighted the company’s ability to translate AI-related demand into revenue growth, citing customer checks and go-to-market signals from hyperscalers and large financial services firms. Radke pointed to new product…

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Trevi Therapeutics announced the attendance of its senior management at several upcoming biotech and therapeutics conferences in June and July 2026 to present updates on its lead investigational therapy Haduvio, aimed at treating chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough conditions. The company highlights Haduvio'…

USBC Supports FDIC’s Proposed Rule to Implement the GENIUS Act

USBC Supports FDIC’s Proposed Rule to Implement the GENIUS Act

USBC, Inc. expresses strong support for the FDIC's proposed rule implementing the GENIUS Act, which provides regulatory clarity and technology-neutral standards for tokenized bank deposits. The company believes these rules will encourage insured depository institutions to adopt tokenized deposit products and enable safer, innovative financial servi…

BofA Clients Trim Single-Stock Holdings but Rotate Back into Tech and ETFs

BofA Clients Trim Single-Stock Holdings but Rotate Back into Tech and ETFs

Bank of America’s latest equity client flow trends report shows clients were net sellers of U.S. single stocks last week while continuing to accumulate equity ETFs. Institutional investors led the single-stock selling, private clients extended their selling streak, and hedge funds were substantial net buyers. Sector flows were mixed, with Technolog…

Aclara Resources: Play the Permitting Time Premium in Heavy Rare Earths

Aclara Resources: Play the Permitting Time Premium in Heavy Rare Earths

Aclara Resources (ARAAF) is a development-stage heavy rare earth play sitting on Chilean concessions and trading at a roughly $800M market cap. Near-term permitting uncertainty has kept the stock subdued, but the company’s tight free float, rising short activity and constructive technicals create an asymmetric swing opportunity: enter at $3.30, sto…

ClearPoint Neuro Shares Leap After UniQure-FDA Discussion on AMT-130 Data

ClearPoint Neuro Shares Leap After UniQure-FDA Discussion on AMT-130 Data

ClearPoint Neuro stock jumped 50% on Wednesday after UniQure disclosed that the U.S. Food and Drug Administration indicated the three-year analysis from its Phase I/II study of AMT-130 could serve as the primary basis for a Biologics License Application seeking accelerated approval in Huntington's disease. AMT-130 is delivered using ClearPoint’s na…

ArcelorMittal, thyssenkrupp Steel and voestalpine call for pragmatic ETS reform, to secure the competitiveness of European steelmaking and help to accelerate decarbonisation

ArcelorMittal, thyssenkrupp Steel and voestalpine call for pragmatic ETS reform, to secure the competitiveness of European steelmaking and help to accelerate decarbonisation

ArcelorMittal, thyssenkrupp Steel, and voestalpine jointly call for pragmatic reforms to the EU Emissions Trading System (ETS) to prevent a steep rise in steel production costs that could threaten Europe's steel industry and manufacturing base. They emphasize the need to pause ETS cost escalation until key enablers for economically viable decarboni…

UK AI Adoption Hits a 'Tipping Point' as Firms Move From Trials to Production, Google Cloud Executive Says

UK AI Adoption Hits a 'Tipping Point' as Firms Move From Trials to Production, Google Cloud Executive Says

Maureen Costello, Google Cloud’s vice president for the UK, Ireland and Sub-Saharan Africa, says artificial intelligence use in Britain has shifted from experimentation to widescale deployment, with organisations beginning to realise returns. Examples include e-commerce tools that have increased customer spend and public-sector applications that sp…

CorVel Launches Marketwise Repricing™ to Deliver Smarter, Market-Based Medical Cost Containment

CorVel Launches Marketwise Repricing™ to Deliver Smarter, Market-Based Medical Cost Containment

CorVel Corporation has launched Marketwise Repricing™, a market-based medical bill repricing solution designed to improve cost containment by integrating real-world reimbursement data into existing bill review workflows. This innovation aims to deliver more consistent and supportable pricing outcomes across varied healthcare markets, addressing gap…

NeoVolta Shares Surge After Needham Starts Coverage With Buy Rating

NeoVolta Shares Surge After Needham Starts Coverage With Buy Rating

NeoVolta Inc. (NASDAQ: NEOV) rallied after Needham initiated coverage with a Buy rating and an $8.00 price target. The brokerage's view shifts emphasis from residential battery products to the company's majority-owned Georgia joint venture, Pendergrass, which is positioned to scale domestic BESS capacity and benefit from regulatory incentives. Fina…